Why Hikma Pharmaceuticals Is a $3.1 Billion Generics Powerhouse
Thanks to Hikma Pharmaceuticals, you probably received help at some point while you were hospitalized in the United States, even if you don't recognize the name.
Its products are used by over 80% of U.S. hospitals. They aren’t flashy, billion-dollar-patent drugs. The boring old injectables — chemotherapy, antibiotics, anesthesia, etc. — on which modern hospitals rely.
And get this — Hikma wasn't founded in New Jersey, Basel, or London. It started with $1,200 in capital in a small rented room in Amman, Jordan.
Today, it's a $3.1 billion multinational company that operates in more than 50 countries. The tale of a tiny Middle Eastern company that decided to take on Big Pharma in some quiet, un-celebrity CEO sort of way, with no billion-dollar ad campaigns or blockbuster patents.
From Nablus to Amman:
Samih Darwazah was born in 1930 in Nablus, Palestine.
He was one of the hundreds of thousands displaced from their homes in 1948 during the Nakba. He escaped to Jordan, then moved on to the United States and graduated from Purdue University's pharmacy school.
He had worked for more than 10 years at Eli Lilly, one of the biggest pharmaceutical firms in America. By the late 1970s, Samih had identified a vast inadequacy: the Arab world was importing most of its drugs, usually at exorbitant rates.
So he thought, why not just make the medicine locally?
Having established Hikma Pharmaceuticals in 1978 on $1200 and having rented a small room in Amman—with no flywheel, no patents—and one goal: exporting good medicine from the region.
Choosing Quality Over Speed :
Hikma began in the most humble form — painful killers, antibiotics, and simple drugs. But Samih realized what many of these fast-growing generics makers failed to realize to their peril: in healthcare, trust trumps speed.
When others made shortcuts, Hikma focused twice as hard on advanced manufacturing and cleanrooms
That commitment paid off. In the 1980s, Hikma received the first approval from the FDA to export medicine to the US, a major turning point for them.
Going Inside the U.S. Market :
TUSUR: For a lot of pharmaceutical companies, this is, you knowLife sciences consulting hype it up as the gravy train. Hikma went a step even further — it made internally.
The company set up a plant in New Jersey in the early 1990s to manufacture not everything, but one of the most difficult categories which is injectables.
It is the sterile drugs hospitals need, things like chemotherapy, anesthesia, and emergency drugs. High Barrier to Entry ( How they are hard but expensive to produce, yet more profitable and fewer competitors)
It was Hikma's singular focus.
A Calculated Expansion :
In 2005, the Company was admitted to the London Stock Exchange, where it became an FTSE 100 company.
It grew from there through targeted acquisitions, not just for size but for capabilities.
That included Baxter's U.S. generics business, injectables operations in the USA and Europe from Boehringer Ingelheim, manufacturing sites at Hollowell (UK) and Lauenau (Germany), as well as branded medicine companies in Egypt and Morocco. It even got into Ethiopia via a partnership.
To this end, by 2024, Hikma operated 29 manufacturing plants across ten countries with more than 8,800 employees.
The Pandemic Stress Test :
As COVID-19 interfered with global supply chains, several drugs had shortages in hospitals. It proved a challenge for Big Pharma Hikma didn’t.
The company's U.S. injectables business was deemed essential and quietly made sure hospitals had the medicines they needed to keep operating. While awaiting big vaccine headlines, Hikma made sure hospitals did not run out of essentials
The Family Business That Became a Global Aggressor
Samih ceded chair to son Sa ̈ıd in 2007. Hikma professionalized far faster than most family businesses, taking on minority investors and breaking up with traditions like family control and centralized decision making.
That enabled Hikma to retain its family values whilst scaling globally.
Endurance Over Disruption :
Hikma never wanted to be a household name. It did not pursue the Next Big Thing in miracle drugs. Rather, it embedded trust, quality, and dependability into its very core.
It nailed the tough niche of injectables and kept on growing by smart M&A. It retained its Mideastern lineage en route to becoming a London-based global player.
In 2020, Hikma generated $3.1 billion in revenue and more than $700 million in operating income; Not bad for a company that launched in an apartment with $1,200.
The Hikma story is not that of disruption but of sheer persistence.
It may be the most valuable strength of all and, in a world of increasingly precarious supply chains and spiraling healthcare costs, it certainly should be.
